Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Wontak Kim, Hillary Haws, Peter Peterson, Clifford J. Whatcott, Steven Weitman, Steven L. Warner, David J. Bearss and Adam Siddiqui-Jain | ||||||||||||
Title | TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/77/13_Supplement/5133 | ||||||||||||
Abstract Text | Cancer Res 2017;77(13 Suppl):Abstract nr 5133 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TP-1287 | TP1287|TP 1287 | TP-1287 is a prodrug of the CDK9 inhibitor Alvocidib with improved oral availability, resulting in enhanced tumor cell toxicity (Cancer Res 2017;77(13 Suppl):Abstract nr 5133). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|